U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146919) titled 'AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer' on Aug. 14.
Brief Summary: The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed combination bemarituzumab and bevacizumab in 3 parallel and independent cohorts of gynecological cancer (endometrium, ovary and cervix).
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Endometrial Carcinoma
Ovarian Cancer
Cervix Cancer
Intervention:
DRUG: Bemarituzumab
Part 1 Dose escalation par...